- New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and long-term complete responses (CRs) to be presented.
- INB-100 continues to demonstrate a favorable safety profile with no dose-limiting toxicities (DLTs) and evidence of robust gamma-delta T cell expansion using recommended Phase 2 dose (RP2D).
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023.
Details for the ASH 2023 presentation are as follows:
Title: INB-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell ...